Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Top Cited Papers
- 14 May 2020
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 181 (4), 865-+
- https://doi.org/10.1016/j.cell.2020.04.020
Abstract
No abstract availableKeywords
Funding Information
- Li Ka Shing Foundation
- Defense Advanced Research Projects Agency
This publication has 50 references indexed in Scilit:
- A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatumNature Methods, 2013
- MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and UsabilityMolecular Biology and Evolution, 2013
- Single-Reaction Genomic Amplification Accelerates Sequencing and Vaccine Production for Classical and Swine Origin Human Influenza A VirusesJournal of Virology, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Influenza vaccine: The challenge of antigenic driftVaccine, 2007
- A review of studies on animal reservoirs of the SARS coronavirusVirus Research, 2007
- Hierarchy among Viral RNA (vRNA) Segments in Their Role in vRNA Incorporation into Influenza A VirionsJournal of Virology, 2006
- Bats Are Natural Reservoirs of SARS-Like CoronavirusesScience, 2005
- The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarityGene, 1980